GlobeNewswire

StackPath and Server Density Merge

Dela

Brings Industry-Leading Monitoring to StackPath's Secure Edge Services Platform

 

DALLAS, May 14, 2018 (GLOBE NEWSWIRE) -- Server Density, a provider of proactive infrastructure monitoring for cloud, servers, and websites, is merging with StackPath, a leading secure edge services platform provider. Server Density enables users to monitor their websites and servers in the cloud or on-prem from a single console and API to easily diagnose problems, maintain uptime and maximize server performance. The service will be integrated and offered as part of the StackPath platform in the very near future.

"We're thrilled to have Server Density become part of our company. It's a perfect fit," said Lance Crosby, founder, chairman and CEO of StackPath. "StackPath has the highest commitment to providing our customers frictionless services, complete visibility into their solutions, and building strong relationships with the open source community and the industry at large. Server Density has followed the same commitments as it built exceptional technologies that are second to none and grew operations at cloud scale."

The Server Density monitoring agent is installed on millions of servers, collecting more than 12-billion metrics each day. The service has more than 100 official integrations with other solutions and platforms, processes more than 300TB of data per month and has availability probes in more than 28 different geographies. Its 1,000+ customers across 75 different countries span all sizes and industries, such as and including the UK's National Health Service (NHS), eCommerce company Firebox, and online game platform Stormancer.

"We created Server Density out of the frustration that monitoring tools were either too expensive, too complex, or both," David Mytton, Server Density co-founder and CEO said. "It's gratifying to see how well our tools have been received, not only by customers, but by developers and companies that have built on the code that we've open sourced. My team and I are excited to bring Server Density into the StackPath platform and accelerate even more evolutionary ways to leverage these technologies."

In addition to its monitoring service, in 2016 Server Density created HumanOps a community that gets people talking about the human aspects of running infrastructure. Companies such as Spotify, PagerDuty, Yelp and Facebook have contributed to sharing ideas and best practices for life on call, dealing with technical debt, fatigue and stress at events around the world, including the UK, US, France, Germany, Poland and more.

"HumanOps is a brilliant and long overdue resource for cloud workers and companies. This industry is evolving faster than any before it, requiring operations of unprecedented scale and solutions at unbelievable speed," said Mr. Crosby. "It takes its toll on people-humans don't have a 100% uptime SLA. We're looking forward to doing even more with HumanOps as part of StackPath."

In December 2015, Server Density raised $1.5 million in seed funding led by SP Ventures. They previously had raised €50k from Seedcamp and funding from angel investors Christoph Janz, Dick Williams, Qamar Aziz, and others. Financial details of the transaction are not being disclosed. Moving forward, the Server Density team in London will serve as the core of StackPath monitoring service team and London will become StackPath's European headquarters.

About StackPath
StackPath is a platform of secure internet services including CDNWAF and DDoS mitigation built at the cloud's edge. StackPath services enable developers at organizations of any size to build protection and performance into any cloud-based solution-from SaaS to web publishing, gaming, media streaming and beyond-without needing cloud security and delivery expertise of their own. More than one million customers, ranging from early-stage companies to Fortune 100 organizations, use StackPath services. Headquartered in Dallas, Texas, StackPath has offices across the U.S. and around the world. For more information, visit stackpath.com and follow StackPath at www.fb.com/stackpathllc and www.twitter.com/stackpath.

About Server Density
Server Density offers SaaS-based scalable infrastructure monitoring to help businesses save time and money. With advanced server and website monitoring alerts, graphing tools and integrations with all major cloud service providers, Server Density's robust and scalable solution helps businesses and IT operations teams be more responsive to issues, make their websites faster and minimize downtime. Founded by David Mytton in 2009 and based in London, Server Density monitors mission critical IT infrastructure for more than 1,000 customers.

For more information, media and analysts may contact
Susie McDonald
StackPath
VP Corporate Communications
susan.mcdonald@stackpath.com 
503-806-3841




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: StackPath via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum